Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000823692 | SCV000964560 | uncertain significance | Charcot-Marie-Tooth disease type 4 | 2023-08-24 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 665415). This variant has not been reported in the literature in individuals affected with FGD4-related conditions. This variant is present in population databases (rs143251785, gnomAD 0.04%). This sequence change replaces serine, which is neutral and polar, with leucine, which is neutral and non-polar, at codon 32 of the FGD4 protein (p.Ser32Leu). |
Molecular Genetics Laboratory, |
RCV001173486 | SCV001336575 | uncertain significance | Charcot-Marie-Tooth disease | criteria provided, single submitter | clinical testing | ||
Ambry Genetics | RCV003169055 | SCV003885685 | uncertain significance | Inborn genetic diseases | 2023-03-14 | criteria provided, single submitter | clinical testing | The c.95C>T (p.S32L) alteration is located in exon 4 (coding exon 2) of the FGD4 gene. This alteration results from a C to T substitution at nucleotide position 95, causing the serine (S) at amino acid position 32 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |